Selective reduction in the expression of UGTs and SULTs, a novel mechanism by which piperine enhances the bioavailability of curcumin in rat

Biopharmaceutics and Drug Disposition

Volumn 38, Issue 1, 2017, Pages 3-19

  Zeng, Xiaohui ^a,b   Cai, Dake ^a,b   Zeng, Qiaohuang ^c   Chen, Zhao ^a,b   Zhong, Guoping ^d   Zhuo, Juncheng ^a,c   Gan, Haining ^a,b   Huang, Xuejun ^a,b   Zhao, Ziming ^a,b   Yao, Nan ^a,b   Huang, Dane ^a,b   Zhang, Chengzhe ^a,c   Sun, Dongmei ^a,b   Chen, Yuxing ^a,b  

^a Guangdong Province Engineering Technology Research Institute of Traditional Chinese Medicine   (China)

^b Pharmacology Research Laboratory of Traditional Chinese Medicine   (China)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

bioavailability; curcumin; piperine; SULT; UGT

Indexed keywords

CURCUMIN; GLUCURONOSYLTRANSFERASE 1A6; PIPERINE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; ARYL SULFOTRANSFERASE; GLUCURONOSYLTRANSFERASE; MONOAMINE-SULFATING PHENOL SULFOTRANSFERASE; PIPERIDINE DERIVATIVE; SULT1A1 PROTEIN, RAT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CACO-2 CELL LINE; CONJUGATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETIC PARAMETERS; PROTEIN EXPRESSION; RAT; TIME-DEPENDENT INHIBITION; ANIMAL; BIOAVAILABILITY; COLON; DRUG EFFECTS; DRUG INTERACTION; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; ARYLSULFOTRANSFERASE; BENZODIOXOLES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; COLON; CURCUMIN; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HUMANS; LIVER; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RATS, SPRAGUE-DAWLEY;

EID: 85010842256     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.2049     Document Type: Article

References (54)

1. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010; 30: 173–199. doi:10.1146/annurev.nutr.012809.104755.
2. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33(10): 940–945. doi:10.1111/j.1440-1681.2006.04468.x.
3. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007; 595: 197–212. doi:10.1007/978-0-387-46401-5_8.
4. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23(1A): 363–398.
5. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002; 244(1–2): 127–135.
6. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15(12): 1867–1876.
7. Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90(5): 1011–1015. doi:10.1038/sj.bjc.6601623.
8. Venkatesan N. Pulmonary protective effects of curcumin against paraquat toxicity. Life Sci 2000; 66(2): PL21–PL28.
9. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999; 27(4): 486–494.
10. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomark Prev 2008; 17(6): 1411–1417. doi:10.1158/1055-9965.EPI-07-2693.
11. Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008; 36(8): 1594–1605. doi:10.1124/dmd.108.020552.
12. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64(4): 353–356. doi:10.1055/s-2006-957450.
13. Durgaprasad S, Pai CG. Vasanthkumar, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122(4): 315–318.
14. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14(14): 4491–4499. doi:10.1158/1078-0432.CCR-08-0024.
15. Ajazuddin A, Alexander A, Qureshi L, et al. Role of herbal bioactives as a potential bioavailability enhancer for active pharmaceutical ingredients. Fitoterapia 2014; 97: 1–14. doi:10.1016/j.fitote.2014.05.005.
16. Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41(6): 615–617. doi:10.1007/BF00314996.
17. Bano G, Amla V, Raina RK, Zutshi U, Chopra CL. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987; 53(6): 568–569. doi:10.1055/s-2006-962814.
18. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006; 20(8): 683–686. doi:10.1002/ptr.1937.
19. Kasibhatta R, Naidu MU. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Drugs RD 2007; 8(6): 383–391.
20. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res 2009; 23(9): 1281–1286. doi:10.1002/ptr.2676.
21. Fong YK, Li CR, Wo SK, et al. In vitro and in situ evaluation of herb–drug interactions during intestinal metabolism and absorption of baicalein. J Ethnopharmacol 2012; 141(2): 742–753. doi:10.1016/j.jep.2011.08.042.
22. Di X, Wang X, Liu Y. Effect of piperine on the bioavailability and pharmacokinetics of emodin in rats. J Pharm Biomed Anal 2015; 115: 144–149. doi:10.1016/j.jpba.2015.06.027.
23. Reen RK, Jamwal DS, Taneja SC, et al. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem Pharmacol 1993; 46(2): 229–238.
24. Singh DV, Godbole MM, Misra K. A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. J Mol Model 2013; 19(1): 227–238. doi:10.1007/s00894-012-1535-8.
25. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302(2): 645–650. doi:10.1124/jpet.102.034728.
26. Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol 2011; 7(6): 721–729. doi:10.1517/17425255.2011.570332.
27. Jin MJ, Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food–drug interaction. J Food Sci 2010; 75(3): H93–H96. doi:10.1111/j.1750-3841.2010.01542.x.
28. Han Y, Chin Tan TM, Lim LY. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol Appl Pharmacol 2008; 230(3): 283–289. doi:10.1016/j.taap.2008.02.026.
29. Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 1985; 232(1): 258–262.
30. Sharma P, Varma MV, Chawla HP, Panchagnula R. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. Farmaco 2005; 60(11–12): 874–883. doi:10.1016/j.farmac.2005.08.007.
31. Volak LP, Hanley MJ, Masse G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2013; 75(2): 450–462. doi:10.1111/j.1365-2125.2012.04364.x.
32. Singh J, Dubey RK, Atal CK. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236(2): 488–493.
33. Suresh D, Srinivasan K. Tissue distribution and elimination of capsaicin, piperine and curcumin following oral intake in rats. Indian J Med Res 2010; 131: 682–691.
34. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4(6): 807–818. doi:10.1021/mp700113r.
35. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol 1980; 18(1): 73–75.
36. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10. doi:10.1186/1472-6882-6-10.
37. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomark Prev 2002; 11(1): 105–111.
38. Hoehle SI, Pfeiffer E, Metzler M. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res 2007; 51(8): 932–938. doi:10.1002/mnfr.200600283.
39. Heath DD, Pruitt MA, Brenner DE, Rock CL. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783(1): 287–295.
40. Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache 2004; 44(2): 142–147.
41. Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 1998; 53(6): 451–458.
42. Nishimura M, Koeda A, Morikawa H, Satoh T, Narimatsu S, Naito S. Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet 2009; 24(2): 139–144.
43. Dluzen DF, Sun D, Salzberg AC, et al. Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p. J Pharmacol Exp Ther 2014; 348(3): 465–477. doi:10.1124/jpet.113.210658.
44. Csala M, Banhegyi G, Benedetti A. Endoplasmic reticulum: a metabolic compartment. FEBS Lett 2006; 580(9): 2160–2165. doi:10.1016/j.febslet.2006.03.050.
45. Basu NK, Kole L, Kubota S, Owens IS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 2004; 32(7): 768–773.
46. Lin Z, Hoult JR, Bennett DC, Raman A. Stimulation of mouse melanocyte proliferation by Piper nigrum fruit extract and its main alkaloid, piperine. Planta Med 1999; 65(7): 600–603. doi:10.1055/s-1999-14031.
47. Abe Y, Fujiwara R, Oda S, Yokoi T, Nakajima M. Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. Drug Metab Pharmacokinet 2011; 26(3): 256–265. doi:10.2133/dmpk.DMPK-10-RG-121.
48. Basu NK, Kole L, Basu M, Chakraborty K, Mitra PS, Owens IS. The major chemical-detoxifying system of UDP-glucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J Biol Chem 2008; 283(34): 23048–23061. doi:10.1074/jbc.M800032200.
49. Suzuki M, Betsuyaku T, Ito Y, et al. Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol 2009; 296(4): L614–L623. doi:10.1152/ajplung.90443.2008.
50. Notoya M, Nishimura H, Woo JT, Nagai K, Ishihara U, Hagiwara H. Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol 2006; 534(1–3): 55–62. doi:10.1016/j.ejphar.2006.01.028.
51. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25(9): 1671–1679. doi:10.1093/carcin/bgh165.
52. Griesser M, Pistis V, Suzuki T, Tejera N, Pratt DA, Schneider C. Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. J Biol Chem 2011; 286(2): 1114–1124. doi:10.1074/jbc.M110.178806.
53. Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 2005; 15(7): 1793–1797. doi:10.1016/j.bmcl.2005.02.039.
54. Jung Y, Xu W, Kim H, Ha N, Neckers L. Curcumin-induced degradation of ErbB2: a role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 2007; 1773(3): 383–390. doi:10.1016/j.bbamcr.2006.11.004.